Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?

Nature Clinical Practice Gastroenterology & Hepatology volume 3, pages 540–541 (2006)Cite this article

boxed-textHanauer SB et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323–333

Adalimumab is effective for inducing remission in patients with active Crohn's disease; a demonstrable response is shown 1 week after administration

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34 (Suppl 1): 12–18

    Article  CAS  Google Scholar 

  2. Targan SR et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029–1035

    Article  CAS  Google Scholar 

  3. Sandborn W et al. (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984–1989

    Article  CAS  Google Scholar 

  4. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285

    Article  CAS  Google Scholar 

  5. Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34 (Suppl 1): 19–22

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. professor of gastroenterology at Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK

    Subrata Ghosh

Authors
  1. Subrata Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Subrata Ghosh.

Ethics declarations

Competing interests

The author has declared associations with the following companies: Abbott, Schering Plough, Centocor and UCB.The author has been a member of the advisory board of Abbott, Schering Plough, Centocor and UCB. He has received honorarium for lecturing in conferences sponsored by Schering Plough and UCB. The author has also received funding from Schering Plough to support research.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghosh, S. How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?. Nat Rev Gastroenterol Hepatol 3, 540–541 (2006). https://doi.org/10.1038/ncpgasthep0605

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0605

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing